Humira approved for use in moderate Crohn's disease

The licensed indications for Humira (adalimumab) have been extended to include the treatment of adults with moderately active Crohn's disease, in addition to use in severe disease.

NICE guidance recommending adalimumab for use in severely active Crohn’s disease has been in place since 2010 | SCIENCE PHOTO LIBRARY
NICE guidance recommending adalimumab for use in severely active Crohn’s disease has been in place since 2010 | SCIENCE PHOTO LIBRARY

The TNF-alpha inhibitor should be used only when the response to conventional therapy, including a corticosteroid and/or an immunosuppressant, is inadequate or when such therapies are not tolerated or are contraindicated. 

View Humira drug record

Further information: AbbVie


Follow MIMS on Twitter

Want news like this straight to your inbox?
Sign up for our bulletins

Read these next

In Depth | Entyvio: gut-selective immunosuppressant for inflammatory bowel disease

In Depth | Entyvio: gut-selective immunosuppressant for inflammatory bowel disease

Takeda has launched Entyvio (vedolizumab) for the treatment...

TNF inhibitors: prescribers reminded of tuberculosis risk

TNF inhibitors: prescribers reminded of tuberculosis risk

The MHRA has issued a reminder to prescribers regarding...

Humira licensed for paediatric Crohn's

Humira licensed for paediatric Crohn's

The licensed indications for Humira (adalimumab) have...

Further licence extension for adalimumab in arthritis

Further licence extension for adalimumab in arthritis

Humira is the first biologic specifically licensed...

Humira: new treatment option for ulcerative colitis

Humira: new treatment option for ulcerative colitis

Humira (adalimumab) can now be prescribed for the treatment...



Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more